Conjugation to PEG as a Strategy to Limit the Uptake of Drugs by the Placenta: Potential Applications for Drug Administration in Pregnancy
| Autor: | Gianfranco Pasut, Frances Beards, Francesca Greco, Abbie Dodd, Az Alddien Natfji, Antonella Grigoletto, Lewis Renshall, Lynda K. Harris, Helen M. I. Osborn, Angelos Evangelinos |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Basal rate
Polymers Drug Compounding Placenta Pharmaceutical Science Pharmacology Polyethylene Glycols Human chorionic gonadotropin chemistry.chemical_compound Pregnancy Lactate dehydrogenase Drug Discovery PEG ratio drug delivery PEG placenta polymer−drug conjugate pregnancy transport Haloperidol medicine Humans Chemistry technology industry and agriculture Pregnancy Complications medicine.anatomical_structure Apoptosis embryonic structures Drug delivery Molecular Medicine Female medicine.drug |
| Zdroj: | Molecular Pharmaceutics. 19:345-353 |
| ISSN: | 1543-8392 1543-8384 |
| Popis: | Here, we evaluated the feasibility of non-prodrug PEG-drug conjugates to decrease the accumulation of drugs within the placental tissues. The results showed that PEG was biocompatible with the human placenta with no alteration of the basal rate of proliferation or apoptosis in term placental explants. No significant changes in the released levels of lactate dehydrogenase and the human chorionic gonadotropin were observed after PEG treatment. The cellular uptake studies revealed that conjugating Cy5.5 and haloperidol to PEG significantly reduced (by up to ∼40-fold) their uptake by the placenta. These findings highlight the viability of novel non-prodrug polymer-drug conjugates to avoid the accumulation of drugs within the placenta. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|